Stemline Therapeutics Inc to Discuss Pivotal Phase 2 Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) - C
Conference Call Stemline Therapeutics Inc
Stemline Therapeutics Inc Conference call will be held on Oct 31, 2017. During the earnings conference call's session Stemline Therapeutics Inc will provide updated information and financial status.
Conference call service enable to conduct an online meeting with several participates at the same time without leaving the room. Earnings call use teleconference platform to conduct an online meeting between the management of a public company, analysts, investors and the media to discuss the financial results during a given reporting period
In order to join the earnings online meeting, contact Stemline Therapeutics Inc for the information on connecting using web conferencing or bridge number and PIN code
Schedule an online meeting with QCONF conference service and get free conference bridge.
We are a clinical stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing proprietary oncology therapeutics. We are currently developing three clinical stage product candidates: SL-401, SL-701, and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor, or IL-3R (CD123), present on a wide range of hematologic cancers. SL-401 is being advanced through a Phase 2 registration-directed clinical trial in patients with blastic plasmacytoid dendritic cell neoplasm, or BPDCN. Data from the initial stage of this ongoing trial demonstrated a high overall response rate, or ORR, with multiple complete responses, or CRs. Patients continue to be followed for overall response, response duration, progression free survival, or PFS, and overall survival, or OS. New patients are also enrolling into the study. We believe that results from this trial could potentially support registration in the United States.Read more Conference Call